Pfizer submits trademark application that suggests it could be launching a direct-to-patient program

Pfiz­er may be the next phar­ma gi­ant to launch a di­rect-to-con­sumer plat­form.

The com­pa­ny ap­plied in April to trade­mark “Pfiz­er for All” for a num­ber of us­es, in­clud­ing on­line re­tail phar­ma­cy ser­vices and mo­bile soft­ware to pro­vide in­for­ma­tion and re­sources to pa­tients. The trade­mark ap­pli­ca­tion was first re­port­ed by the Fi­nan­cial Times. Un­named sources told the FT in May that Pfiz­er was work­ing on an on­line plat­form for or­der­ing prod­ucts such as its Covid-19 an­tivi­ral Paxlovid and mi­graine treat­ment Za­vzpret. (End­points News is a part of FT Spe­cial­ist, a unit of the Fi­nan­cial Times.)

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.